Cargando…
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
Cardiovascular disease (CVD) remains the leading cause of death in the USA. Several risk factors have been identified, and obesity has become one of prominent concern. Excessive weight is considered a risk factor for CVD based on evidence linking it to a hypercoagulable state. Considering the preval...
Autores principales: | Ashton, Veronica, Mudarris, Lana, Moore, Kenneth T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089078/ https://www.ncbi.nlm.nih.gov/pubmed/32803514 http://dx.doi.org/10.1007/s40256-020-00434-w |
Ejemplares similares
-
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2021) -
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
por: Alberts, Mark J., et al.
Publicado: (2022) -
Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
por: Berger, Jeffrey S., et al.
Publicado: (2021) -
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States
por: Berger, Jeffrey S., et al.
Publicado: (2022) -
Rivaroxaban Versus Warfarin for Management of Obese African Americans
With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective
Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)